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Resveratrol,  a polyphenolic  phytoalexin,  is produced  by  plants  in  response  to infection  and has  antibacte-
rial  activity.  Haemophilus  ducreyi  is  a Gram-negative  bacterium  that  is  the causative  agent  of the  sexually
transmitted  disease  chancroid.  This  study  employed  minimum  cidal  concentration  (MCC)  assays  to  eval-eywords:
aemophilus ducreyi
hancroid
actobacillus
esveratrol
icrobicide
uate the  potential  of resveratrol  as a microbicide  against  H.  ducreyi.  Five  class  I  and four  class  II strains
of  H.  ducreyi  tested  had  MCCs  ≤500  g/mL.  Resveratrol  was  also  tested  against  Lactobacillus  spp.,  part
of the  natural  vaginal  ﬂora.  Representative  strains  of  Lactobacillus  were  co-cultured  with  H. ducreyi  and
500 g/mL  resveratrol;  in  all cases,  Lactobacillus  was  recovered  in  greater  numbers  than  H. ducreyi.  These
results  show  that  resveratrol  is not  only  bacteriostatic  but is  bactericidal  to H. ducreyi,  conﬁrming  the
compound’s  potential  for use  as  a topical  microbicide  to  prevent  chancroid.
© 2013 Elsevier B.V. and the International Society of Chemotherapy. . Introduction
Resveratrol (3,5,4′-trihydroxystilbene) is a polyphenolic phy-
oalexin produced by a variety of ﬂowering plants in response
o unfavourable environmental conditions such as fungal infec-
ion or injury [1].  It is commonly found in dietary products,
ncluding peanuts, grapes and red wine [2].  Resveratrol has demon-
trated antimicrobial activity against numerous Gram-negative and
ram-positive bacterial pathogens, including carcinogenic strains
f Helicobacter pylori [2,3]. The antifungal and antiviral properties
f resveratrol have also been demonstrated [4,5]. The compound is
hought to work by inhibiting the activity of ATPases, thus preven-
ing the production or utilisation of energy [3].
Haemophilus ducreyi is a fastidious Gram-negative bacillus and
s the aetiological agent of chancroid, a sexually transmitted genital
lcer disease [6].  Haemophilus ducreyi strains are grouped into two
lasses based on their outer membrane components [7].  Chancroid
acilitates the acquisition and transmission of human immunode-
ciency virus type 1 (HIV-1) [6].  Like other sexually transmitted
nfections (STIs), chancroid can interact with HIV via genital ulcers,
hich increase the infectiousness of HIV-positive individuals and
he susceptibility of HIV-negative individuals [8]. Chancroid is
ndemic to regions of Africa and Asia, but because these areas lack
iagnostic tests for H. ducreyi the actual prevalence of chancroid is
nknown [6].
In recent decades, strains of H. ducreyi have acquired plasmid-
ediated mechanisms of resistance to several classes of antibiotics
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Open ac[9].  The recommended treatment regimens for chancroid rely on
azithromycin, ceftriaxone, ciproﬂoxacin or erythromycin, but H.
ducreyi isolates with intermediate resistance to either ciproﬂoxacin
or erythromycin have been identiﬁed [10]. Although a single dose of
azithromycin (1 g orally) or ceftriaxone (250 mg  intramuscularly)
remains effective in treating chancroid, their high costs evoke con-
cerns that inadequate doses will be taken, supporting the selection
of resistance to these drugs [8].  The rise of antibiotic resistance
and the prevalence of chancroid in resource-poor environments
have necessitated the development of alternative treatment and
prevention strategies.
Unlike antibiotics, microbicides prevent transmission rather
than treating infection; microbicides must also reduce a microbe’s
infectivity within minutes rather than days [11]. An ideal microbi-
cide would prevent transmission of pathogens while maintaining
an environment of healthy normal ﬂora [11]. In most women,
the vaginal environment is dominated by the genus Lactobacil-
lus,  including species such as Lactobacillus crispatus, Lactobacillus
jensenii, Lactobacillus gasseri,  Lactobacillus iners and Lactobacil-
lus vaginalis [12]. In addition, a microbicide designed to prevent
STIs should have activity against multiple STI-causing pathogens.
Resveratrol has been shown to selectively inhibit the growth of
Neisseria gonorrhoeae, the causative agent of gonorrhoea, although
Docherty et al. did not test resveratrol against natural vaginal ﬂora
[13].
This study tested the microbicidal activity of resveratrol against
both classes of H. ducreyi as well as several of the most com-
Open access under CC BY-NC-ND license. mon vaginal strains of Lactobacillus. Minimum cidal concentration
(MCC) assays were performed on monocultures and co-cultures of
H. ducreyi and lactobacilli to assess the viability of resveratrol as a
microbicide for chancroid prevention. Resveratrol was found to be
cess under CC BY-NC-ND license. 
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Table 1
Minimum cidal concentration (MCC) of resveratrol against Haemophilus ducreyi
strains.
Strain Class MCC (g/mL)a
35000HP I 500
HMC56 I 500
HD85-023233 I 500
HD188 I 500
HD183 I 500
HMC112 II 250
33921 II 250
DMC64 II 250
CIP542ATCC II 250
a78 E.M. Nawrocki et al. / International Journ
ore bactericidal to H. ducreyi than to lactobacilli, recommending
ts use as a topical microbicide for chancroid prevention.
. Materials and methods
.1. Resveratrol
Trans-resveratrol (MegaResveratrol®; Candlewood Stars Inc.,
anbury, CT) was dissolved in ethanol and stored protected from
ight at 4 ◦C until use. To prevent isomerisation to cis-resveratrol,
hich can occur after 30 days under ﬂuorescent lighting, fresh
tocks of resveratrol solutions were made monthly [1].
.2. Bacterial cultures
The following strains of H. ducreyi (kindly provided by Stan
pinola, Indiana University School of Medicine, Indianapolis, IN)
ere used in this study (class in parentheses): 35000HP (I); HMC56
I); HD85-023233 (I); HD188 (I); HD183 (I); HMC112 (II); DMC64
II); 33921 (II); and CIP542ATCC (II). The following vaginal Lacto-
acillus isolates (kindly provided by Sharon Hillier, University of
ittsburgh, Pittsburgh, PA) were also used: L. vaginalis Lac08(vl)-5
/14/04; and L. vaginalis Lac11(vl)-b 7/14/04. One gastrointesti-
al Lactobacillus strain (Lactobacillus reuteri CF48-3A HM-102) was
btained from BEI Resources (Manassas, VA).
All H. ducreyi strains were cultured on chocolate agar (GC Agar
ase, 1% haemoglobin; Alpha Biosciences, Baltimore, MD)  supple-
ented with 1% IsoVitaleXTM (Becton Dickinson, Franklin Lakes,
J) at 33 ◦C in a 10% CO2 incubator. Lactobacilli strains were grown
n de Man–Rogosa–Sharpe Lactobacillus agar (Becton Dickinson)
t 35 ◦C in a 5% CO2 incubator. Co-cultures were grown on choco-
ate agar at 35 ◦C in a 5% CO2 incubator. All cultures were revived
rom frozen stocks and were subcultured once before an assay was
erformed.
.3. Minimum cidal concentration assay
An MCC  assay was used to determine the microbicidal activ-
ty of resveratrol against various strains of bacteria [11]. Bacteria
ere suspended in phosphate-buffered saline (PBS) to match the
urbidity of a 0.5 McFarland standard. The suspension was then
iluted 1:10 in PBS. Resveratrol was added to brain–heart infu-
ion (BHI) medium (EMD Millipore, Billerica, MA)  supplemented
ith 0.1% potato starch (Difco Laboratories, Detroit, MI), 5% haemin
Spectrum Chemicals and Laboratory Products, New Brunswick, NJ)
nd 1% IsoVitaleXTM (Becton Dickinson) to give a test solution of
he desired concentration of resveratrol, and 80 L was added to
ach well of a 96-well microtitre plate (USA Scientiﬁc, Ocala, FL).
n monocultures, 20 L of the bacterial suspension was  added to
ach well to yield a total volume of 100 L per well. In co-cultures,
0 L of the H. ducreyi suspension and 10 L of the Lactobacillus
uspension were added to each well.
After 30 min  of incubation, an aliquot from each well was serially
iluted ten-fold in saline and the dilutions were plated and incu-
ated for 48 h. Colonies were then counted to determine CFU/mL.
he log (CFU/mL) of the resveratrol test solution was compared
ith the log (CFU/mL) of the bacterial solution without resveratrol
dded. The MCC  was deﬁned as the lowest concentration causing
 4-log (99.99%) decrease in viable bacteria. Because 500 g/mL
esveratrol was required for cidal activity against class I H. ducreyi,
his concentration was used for all co-culture assays.The MCC  is the lowest concentration required to cause a 4-log decrease in viable
bacteria relative to a control without resveratrol after 30 min of exposure; nine
replicates for all strains except CIP542ATCC, which had six replicates.
3. Results and discussion
Class II strains were more susceptible to resveratrol than class
I strains (Table 1). A control solution of 5% ethanol in BHI–starch
complete medium was  tested to conﬁrm that the decrease in viable
bacteria was due to resveratrol and not its solvent; in no case did
ethanol cause more than a 1-log decrease in CFU/mL (data not
shown).
Because class I H. ducreyi required 500 g/mL resveratrol to be
killed in vitro, this concentration was tested against species of the
Lactobacillus genus to determine any deleterious effects a microbi-
cide might have on natural ﬂora. Each of the three Lactobacillus
strains in this study was  treated with 500 g/mL resveratrol in
monoculture; in no case did the treatment cause a decrease >2-log
(data not shown). The Lactobacillus strains were then co-cultured
with H. ducreyi to determine the interaction effects among the two
species and the resveratrol test solution. The results were consis-
tent with those of the monocultures, with H. ducreyi being more
susceptible than Lactobacillus to the cidal effects of resveratrol.
Except in the case of the HMC112 co-cultures, 500 g/mL resvera-
trol was cidal (i.e. caused a 4-log decrease) to H. ducreyi but had very
little effect on lactobacilli, causing <1-log decrease (Table 2). When
co-cultured with HMC112, the two  Lactobacillus strains were more
susceptible to resveratrol, but neither decreased >4-log relative to
the untreated control (Table 2).
One explanation for altered susceptibilities to resveratrol is dif-
ferential production of ATPases, as hypothesised by Martini et al.
[3]. Certain H. pylori strains use ATPases to adapt to acidic condi-
tions, whilst strains colonising a less acidic environment may be
more vulnerable to resveratrol because of reduced ATPase produc-
tion [3]. Lactobacilli, being accustomed to the low vaginal pH, may
employ ATPases in a similar strategy. If H. ducreyi expresses fewer
ATPases than Lactobacillus spp., this could account for its greater
susceptibility to resveratrol.
Although these Lactobacillus strains are a few of many that may
make up the vaginal environment, their lower susceptibility to
resveratrol supports the compound’s potential as a microbicide
for preventing STIs. Variation in the cidal and inhibitory activity
of resveratrol against lactobacilli suggests that testing a broader
sample of natural ﬂora strains could be beneﬁcial.
Resveratrol has previously been described as an antimicro-
bial compound based on its minimum inhibitory concentrations
(MICs) against other organisms. The MICs of resveratrol against
the Gram-positive species Bacillus cereus,  Staphylococcus aureus and
Enterococcus faecalis ranged from 50 g/mL to 200 g/mL [2]. Paulo
et al. were unable to determine the MICs of Gram-negative bacte-
ria, which exceeded 400 g/mL, because resveratrol was  insoluble
in their culture medium above this concentration [2].  The current
study achieved higher concentrations of resveratrol in vitro and
was able to conﬁrm the compound’s antimicrobial activity against
E.M. Nawrocki et al. / International Journal of Antimicrobial Agents 41 (2013) 477– 479 479
Table 2
Log decrease of resveratrol-treated organisms relative to untreated controla.
Organisms co-cultured Log decrease (mean ± S.D.; n = 9)
Haemophilus ducreyi Lactobacillus spp. H. ducreyi Lactobacillus spp.
35000HP L. vaginalis 08 8.59 ± 0.31 0.01 ± 0.42
L.  vaginalis 11 8.67 ± 0.50 0.01 ± 0.39
L.  reuteri 8.54 ± 0.92 0.57 ± 0.51
HMC56 L.  vaginalis 08 7.92 ± 0.87 −0.25 ± 0.87
L.  vaginalis 11 7.81 ± 1.04 0.35 ± 0.67
L.  reuteri 8.67 ± 0.91 −0.39 ± 0.41
HD85-023233 L.  vaginalis 08 8.59 ± 0.31 0.23 ± 0.52
L.  vaginalis 11 9.46 ± 0.13 0.34 ± 0.61
L.  reuteri 8.83 ± 0.26 0.05 ± 0.86
HD188 L.  vaginalis 08 8.33 ± 0.50 −0.76 ± 0.73
L.  vaginalis 11 8.48 ± 0.64 0.23 ± 0.68
L.  reuteri 8.67 ± 0.50 0.34 ± 0.49
HD183 L.  vaginalis 08 7.97 ± 1.03 0.15 ± 0.37
L.  vaginalis 11 8.33 ± 1.00 −0.11 ± 0.59
L.  reuteri 7.59 ± 0.78 0.28 ± 0.75
HMC112 L.  vaginalis 08 3.97 ± 0.00 2.55 ± 0.34
L.  vaginalis 11 4.03 ± 0.00 3.30 ± 0.07
DMC64 L.  vaginalis 08 6.27 ± 0.00 −0.22 ± 0.16
L.  vaginalis 11 6.61 ± 0.00 −0.28 ± 0.39
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[.D., standard deviation.
a Co-cultures were exposed to 500 g/mL resveratrol for 30 min. One H. ducreyi 
onsidered cidal.
. ducreyi. In addition, we show that unlike traditional antibiotics,
hich have much lower MICs against H. ducreyi but are designed
o treat rather than prevent infections [9],  resveratrol is not only
nhibitory but is bactericidal to H. ducreyi.
Future research should consider the efﬁcacy and toxicity of
esveratrol when present in the vaginal environment. A microbicide
hould remain active in the presence of blood and/or semen, which
ay  be present in the vagina as a result of infection, menstruation
r intercourse and which change the local pH [14]. Furthermore,
n the past, microbicidal candidates have demonstrated cytotoxic-
ty to epithelial cells and irritation to the mucus membrane [15].
f resveratrol is to be used as a microbicide applied directly to the
aginal wall, its effects in vivo must be addressed.
Microbicides are a promising method of STI and HIV prevention
ecause they are female-controlled. Although the female condom
s one such current and effective method of STI prevention, its
isadvantages include high cost, difﬁculty of use, pre-planning
ntercourse, and reaction of partners [8].  Microbicides present a
ethod of protection that may  not require the knowledge or accep-
ance of a partner. The prevalence of coercive sexual intercourse
here it is difﬁcult for women to negotiate for safer sex neces-
itates an inconspicuous female-controlled method of protection
gainst H. ducreyi infection and HIV.
These in vitro results indicate that a solution of 500 g/mL
esveratrol is cidal to both classes of H. ducreyi but not to three
epresentative species of Lactobacillus. Assays with co-cultures of
. ducreyi and lactobacilli indicated similar results as the mono-
ultures of each species, indicating that the killing of H. ducreyi
y resveratrol is not affected by the presence of lactobacilli and
fﬁrming the potential of resveratrol as a topical microbicide for
he prevention of chancroid.
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